Zhu, J., Wang, Y., Duan, J., Bai, H., Wang, Z., Wei, L., . . . Wang, J. (2012). DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer. BioMed Central.

Zhu, Jian, et al. DNA Methylation Status of Wnt Antagonist SFRP5 Can Predict the Response to the EGFR-tyrosine Kinase Inhibitor Therapy in Non-small Cell Lung Cancer. BioMed Central, 2012.

Zhu, Jian, et al. DNA Methylation Status of Wnt Antagonist SFRP5 Can Predict the Response to the EGFR-tyrosine Kinase Inhibitor Therapy in Non-small Cell Lung Cancer. BioMed Central, 2012.